



January 23, 2020

**BSE Limited**  
P. J. Towers  
Dalal Street, Fort  
**Mumbai - 400 001**

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E),  
**Mumbai - 400 051**

Dear Sirs,

**Sub.: Schedule of Investor Conference Call for Jubilant Life Sciences Limited - Unaudited Financial Results for the quarter ended December 31, 2019**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on January 31, 2020 after submission of the financial results for the quarter ended December 31, 2019 to the Stock Exchanges. Details of the Conference Call are attached.

This is for information and record.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com



Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624

**Noida, Thursday, January 23, 2020**

**Conference call on Friday, January 31, 2020 at 05:00 pm IST**

The management team of Jubilant Life Sciences Limited (Jubilant) – an integrated global pharmaceutical and life sciences company will host a **conference call for analysts and investors on Friday, January 31, 2020 at 05:00 pm IST**. The call will commence with a brief management discussion on the financial performance for the quarter ended December 31, 2019, followed by an interactive Question & Answer session.

Mr. Shyam S. Bhartia, Chairman, Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Mr. R Sankaraiah, Executive Director - Finance, Mr. Alok Vaish, CFO Designate, Mr. Ravi Agrawal, Head - Investor Relations and Mr. Vineet Mayer, Sr. Manager - Investor Relations, Jubilant Life Sciences Limited, will represent the management team at the conference call.

<b>Conference Dial-In Numbers</b>	
<b>Universal Access:</b>	<b>+ 91 22 6280 1141</b> <b>+ 91 22 7115 8042</b>
<b>Local Access Number:</b>	<b>+91-7045671221</b> <i>Available all over India.</i>
<b>Toll Free Number:</b>	USA: <b>1 866 746 2133</b> UK: <b>0 808 101 1573</b> Singapore: <b>800 101 2045</b> Hong Kong: <b>800 964 448</b>
<b>Pre-registration:</b>	To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link     You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.
<b>Replay Facility:</b>	Available from January 31 to February 08, 2020 <b>Dial in No.:</b> +91 22 7194 5757 <b>Playback ID:</b> 57866#

**-ENDS -**

## **About Jubilant Life Sciences Limited**

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Pharma business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics. DDS provides innovation and collaborative research through two world class research centers in Bangalore and Noida in India and Proprietary Drug Discovery is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Life Sciences Limited has a team of around 7,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

### **For more information please contact:**

Ravi Agrawal / Vineet Mayer  
Jubilant Life Sciences Limited  
Ph: +91-120 4361002 / 21  
E-mail: ravi.agrawal@jubl.com  
vineet.mayer@jubl.com

Siddharth Rangnekar / Karl Kolah  
CDR India  
Ph: +91-22 6645 1209 / 20  
E-mail: siddharth@cdr-india.com  
karl@cdr-india.com

**Disclaimer:** Statements made on the call relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.